强生医疗科技（Johnson & Johnson MedTech）业务板块在全球范围内涵盖外科、骨科、眼科以及心血管及专业解决方案等领域，主要品牌包括：Ethicon,DePuy Synthes,Biosense Webster,Cerenovus,Acclarent和ACUVUE。1月25日，强生公布2021年全球业绩，全年实现总收入937.75亿美元，同比增长13.6%；其中制药业务收入520.8亿美元（...
Learn the latest about this common procedure and how Johnson & Johnson MedTech is innovating to improve patient outcomes. Read more April 16, 2024 What you need to know about Johnson & Johnson’s 2024 first-quarter earnings Here’s an infographic breakdown of the company’s first-quarter...
About Johnson & Johnson MedTech Johnson & Johnson MedTech offers healthcare expertise and technology to transform the future of medical intervention. The company develops and provides surgical, orthopedic, medical equipment, and interventional solutions. It was founded in 1998 and is based in Warsaw,...
随着 Shockwave 的加入,强生公司将把其 MedTech 心血管产品组合扩展到心血管干预领域增长最快、以创新为导向的两个领域——冠状动脉疾病 (CAD) 和外周动脉疾病 (PAD)。在此次交易之前,强生医疗科技成功收购了心脏康复领域的领导者 Abiomed,以及最近收购的 Laminar,后者是非瓣膜性心房颤动 (AFib) 患者左心耳消除术的...
For over 130 years, Johnson & Johnson has maintained a tradition of quality and innovation. Learn about the products, people and history that make up our company.
vision to develop and deliver an innovative solution to help patients live without the fear of stroke, or the need for long-term use of blood thinners,” said Randy Lashinski, President & CEO, Laminar. “We are looking forward to advancing this vision as part ofJohnson & JohnsonMedTech....
Johnson Medtech offers innovative solutions to design and manufacture high quality medical device subsystems.
Johnson Medtech offers innovative solutions to design and manufacture high quality medical device subsystems.
Johnson & Johnson MedTech Amanda Care y Doole Health son las start-ups ganadoras del MedTech Innovation Open Challenge 2022 Síguenos: Check us out on RSS Compartir esta página: Novedades Microsoft Copilot Microsoft 365 Aplicaciones de Windows 11 Educación Microsoft Educación Dispositivos ...
As previously announced, the transaction will accelerate pro forma MedTech and Johnson & Johnson enterprise revenue growth. It is also expected to be slightly dilutive to neutral to adjusted earnings per share in the first year, considering the impact of financing, and then accretive by ...